GlassScriptPhysician profile
Laura Lienemann
NPI 1538526538
$1,854.43
in general payments reported to CMS, 2019-2025
21 companies · $773 in 2025
The $773 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $172 · 2023: $420 · 2024: $489 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626 · Education: $55.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,626.01 |
| Education | $55.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $316.53 | 2022-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Csl Behring | $312.61 | 2022-2025 | Hizentra, Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $282.13 | 2022-2025 | Cuvitru, Takhzyro, Hyqvia |
| Genzyme Corporation | $217.76 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $147.12 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $131.99 | 2022-2025 | Dupixent |
| Optinose US, INC. | $84.32 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $55.99 | 2025 | |
| Genentech USA, INC. | $50.17 | 2024-2025 | Xolair |
| Biocryst US Sales Co., LLC | $44.67 | 2022-2025 | Orladeyo |
| Hikma Pharmaceuticals USA | $32.65 | 2024-2025 | Ryaltris |
| Azurity Pharmaceuticals, INC. | $30.30 | 2025 | Alvesco |
| Amgen INC. | $29.69 | 2022-2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $16.75 | 2025 | |
| Ionis Pharmaceuticals, INC. | $15.83 | 2025 | Dawnzera |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greer Laboratories, INC. | $15.28 | 2024 | Palforzia |
| Teva Pharmaceuticals USA, INC. | $15.21 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.72 | 2025 | Xhance |
| Kaleo, INC. | $14.56 | 2024 | Auvi-Q |
| Astrazeneca Pharmaceuticals LP | $14.16 | 2024 | Airsupra |
| Aimmune Therapeutics, INC. | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Lienemann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.